Literature DB >> 24919170

What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia?

Philip D Harvey1.   

Abstract

Cognitive deficits in schizophrenia are important predictors of impairment in most functional domains and are a critical therapeutic target. These deficits appear at or before the onset of illness, are stable across time in most patients, and can be improved by cognitive remediation treatments. Recent evidence, however, suggests that cognitive function does not necessarily follow a pattern of age-related decline. Several studies evaluated this pattern of decline in schizophrenia patients compared to both natural aging and degenerative conditions such as Alzheimer's disease. Age-related differences were not comparable to either normal aging or Alzheimer's disease. Older patients with an extensive history of illness and protracted institutionalization have shown a greater progressive decline. These deficits were also observed in older patients who were no longer institutionalized, with these patients demonstrating decline in functional capacity across time compared to healthy controls and patients with no lengthy institutional stay. There were 2 clear conclusions from this body of data. First, there appear to be 2 separate periods of deterioration in schizophrenia patients. These patients appear to decline the most at 2 key time points; the first occurs some time prior to the first psychotic episode and the second begins at approximately 65 years of age. The second important conclusion is that these 2 important periods of time may be the time point at which an aggressive intervention may have the greatest impact. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24919170     DOI: 10.4088/JCP.13065su1.08

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  19 in total

Review 1.  Physical Exercise Alleviates Health Defects, Symptoms, and Biomarkers in Schizophrenia Spectrum Disorder.

Authors:  Trevor Archer; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-07-15       Impact factor: 3.911

2.  Predictors of current functioning and functional decline in schizophrenia.

Authors:  Jamie Joseph; William S Kremen; Carol E Franz; Stephen J Glatt; Joyce van de Leemput; Sharon D Chandler; Ming T Tsuang; Elizabeth W Twamley
Journal:  Schizophr Res       Date:  2017-01-28       Impact factor: 4.939

3.  Telomere Length and CCL11 Levels are Associated With Gray Matter Volume and Episodic Memory Performance in Schizophrenia: Evidence of Pathological Accelerated Aging.

Authors:  Leticia Sanguinetti Czepielewski; Raffael Massuda; Bruna Panizzutti; Lucas Kich Grun; Florencia María Barbé-Tuana; Antonio Lucio Teixeira; Deanna M Barch; Clarissa S Gama
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

4.  Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis.

Authors:  Debra L Foley; Andrew Mackinnon; Vera A Morgan; Gerald F Watts; David J Castle; Anna Waterreus; Cherrie A Galletly
Journal:  Schizophr Bull       Date:  2016-05-05       Impact factor: 9.306

Review 5.  Recent Advances in the Early Intervention in Schizophrenia: Future Direction from Preclinical Findings.

Authors:  Kenji Hashimoto
Journal:  Curr Psychiatry Rep       Date:  2019-07-05       Impact factor: 5.285

6.  The impact of psychosis on the course of cognition: a prospective, nested case-control study in individuals at clinical high-risk for psychosis.

Authors:  R E Carrión; D McLaughlin; A M Auther; R Olsen; C U Correll; B A Cornblatt
Journal:  Psychol Med       Date:  2015-07-14       Impact factor: 7.723

Review 7.  Neurodegenerative model of schizophrenia: Growing evidence to support a revisit.

Authors:  William S Stone; Michael R Phillips; Lawrence H Yang; Lawrence S Kegeles; Ezra S Susser; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2022-03-25       Impact factor: 4.662

8.  Systematic review of global functioning and quality of life in people with psychotic disorders.

Authors:  A G Nevarez-Flores; K Sanderson; M Breslin; V J Carr; V A Morgan; A L Neil
Journal:  Epidemiol Psychiatr Sci       Date:  2018-10-01       Impact factor: 6.892

9.  Long-term Changes in Cognitive Functioning in Individuals With Psychotic Disorders: Findings From the Suffolk County Mental Health Project.

Authors:  Anne-Kathrin J Fett; Eva Velthorst; Abraham Reichenberg; Camilo J Ruggero; Jennifer L Callahan; Laura J Fochtmann; Gabrielle A Carlson; Greg Perlman; Evelyn J Bromet; Roman Kotov
Journal:  JAMA Psychiatry       Date:  2020-04-01       Impact factor: 21.596

10.  Screening for cognitive impairment in schizophrenia: Psychometric properties of the German version of the Screen for Cognitive Impairment in Psychiatry (SCIP-G).

Authors:  Gabriele Sachs; Iris Lasser; Scot E Purdon; Andreas Erfurth
Journal:  Schizophr Res Cogn       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.